These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 32514935)
1. Renin-angiotensin system inhibition in COVID-19 patients. de Vries AAF Neth Heart J; 2020 Jul; 28(7-8):396-405. PubMed ID: 32514935 [TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 and the Angiotensin-Converting Enzyme 2 Receptor: Angiotensin-Converting Enzyme Inhibitor/Angiotensin 2 Receptor Blocker Utilization and a Shift Towards the Renin-Angiotensin-Aldosterone System Classical Pathway. Felber R; New W; Riskin SI Cureus; 2024 Mar; 16(3):e55563. PubMed ID: 38576704 [TBL] [Abstract][Full Text] [Related]
4. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19. Kai H; Kai M Hypertens Res; 2020 Jul; 43(7):648-654. PubMed ID: 32341442 [TBL] [Abstract][Full Text] [Related]
5. Angiotensin converting enzyme 2 at the interface between renin-angiotensin system inhibition and coronavirus disease 2019. Siri-Angkul N; Chattipakorn SC; Chattipakorn N J Physiol; 2020 Oct; 598(19):4181-4195. PubMed ID: 32710575 [TBL] [Abstract][Full Text] [Related]
6. Potential Implications of Angiotensin-converting Enzyme 2 Blockades on Neuroinflammation in SARS-CoV-2 Infection. Paul D; Mohankumar SK; Thomas RS; Kheng CB; Basavan D Curr Drug Targets; 2022; 23(4):364-372. PubMed ID: 34732115 [TBL] [Abstract][Full Text] [Related]
7. COVID-19, Angiotensin-Converting Enzyme 2 and Renin-Angiotensin System Inhibition: Implications for Practice. Katsi V; Pavlidis G; Charalambous G; Tousoulis D; Toutouzas K Curr Hypertens Rev; 2022; 18(1):3-10. PubMed ID: 33475077 [TBL] [Abstract][Full Text] [Related]
8. Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers. Danser AHJ; Epstein M; Batlle D Hypertension; 2020 Jun; 75(6):1382-1385. PubMed ID: 32208987 [TBL] [Abstract][Full Text] [Related]
9. The divergent protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on clinical outcomes of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Xie Q; Tang S; Li Y Ann Palliat Med; 2022 Apr; 11(4):1253-1263. PubMed ID: 34775774 [TBL] [Abstract][Full Text] [Related]
10. The Renin-Angiotensin System, Hypertension, and SARS-CoV-2 Infection: a Review. Gathiram P; Mackraj I; Moodley J Curr Hypertens Rep; 2021 Mar; 23(4):17. PubMed ID: 33768439 [TBL] [Abstract][Full Text] [Related]
11. Associations Between the Use of Renin-Angiotensin System Inhibitors and the Risks of Severe COVID-19 and Mortality in COVID-19 Patients With Hypertension: A Meta-Analysis of Observational Studies. Dai XC; An ZY; Wang ZY; Wang ZZ; Wang YR Front Cardiovasc Med; 2021; 8():609857. PubMed ID: 33981731 [TBL] [Abstract][Full Text] [Related]
12. Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Angiotensin-Converting Enzyme 2 Levels: A Comprehensive Analysis Based on Animal Studies. Kriszta G; Kriszta Z; Váncsa S; Hegyi PJ; Frim L; Erőss B; Hegyi P; Pethő G; Pintér E Front Pharmacol; 2021; 12():619524. PubMed ID: 33762942 [TBL] [Abstract][Full Text] [Related]
13. Therapy with RAS inhibitors during the COVID-19 pandemic. Spaccarotella C; Mazzitelli M; Migliarino S; Curcio A; De Rosa S; Torti C; Indolfi C J Cardiovasc Med (Hagerstown); 2021 May; 22(5):329-334. PubMed ID: 33795584 [TBL] [Abstract][Full Text] [Related]
14. Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers During the COVID-19 Pandemic: A Modeling Analysis. Sadria M; Layton AT PLoS Comput Biol; 2020 Oct; 16(10):e1008235. PubMed ID: 33031368 [TBL] [Abstract][Full Text] [Related]
15. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19). Mehta N; Kalra A; Nowacki AS; Anjewierden S; Han Z; Bhat P; Carmona-Rubio AE; Jacob M; Procop GW; Harrington S; Milinovich A; Svensson LG; Jehi L; Young JB; Chung MK JAMA Cardiol; 2020 Sep; 5(9):1020-1026. PubMed ID: 32936273 [TBL] [Abstract][Full Text] [Related]
16. Role and mechanism of angiotensin-converting enzyme 2 in acute lung injury in coronavirus disease 2019. Liu MY; Zheng B; Zhang Y; Li JP Chronic Dis Transl Med; 2020 Jun; 6(2):98-105. PubMed ID: 32550040 [TBL] [Abstract][Full Text] [Related]
17. Impact of in-hospital discontinuation with angiotensin receptor blockers or converting enzyme inhibitors on mortality of COVID-19 patients: a retrospective cohort study. de Abajo FJ; Rodríguez-Miguel A; Rodríguez-Martín S; Lerma V; García-Lledó A; BMC Med; 2021 May; 19(1):118. PubMed ID: 33980231 [TBL] [Abstract][Full Text] [Related]
18. Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients. Rossi GP; Sanga V; Barton M Elife; 2020 Apr; 9():. PubMed ID: 32250244 [TBL] [Abstract][Full Text] [Related]
19. Considerations on the use of antihypertensive blockers of the renin-angiotensin system in adults and children in the face of the COVID-19 pandemic. Vázquez-Cornejo E Bol Med Hosp Infant Mex; 2020; 77(5):274-281. PubMed ID: 33064690 [TBL] [Abstract][Full Text] [Related]
20. Renin-angiotensin system blockade on angiotensin-converting enzyme 2 and TMPRSS2 in human type II pneumocytes. Silva MG; Falcoff NL; Corradi GR; Alfie J; Seguel RF; Tabaj GC; Iglesias LI; Nuñez M; Guman GR; Gironacci MM Life Sci; 2022 Mar; 293():120324. PubMed ID: 35032553 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]